Abstract
The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management.
Keywords
Adverse effectBlockadeImmune systemImmune checkpointMedicineImmunologyImmunotherapyInternal medicineReceptor
Affiliated Institutions
Related Publications
Cancer immunotherapy using checkpoint blockade
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we ...
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...
Publication Info
- Year
- 2018
- Type
- review
- Volume
- 378
- Issue
- 2
- Pages
- 158-168
- Citations
- 4292
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
4292
OpenAlex
Cite This
Michael A. Postow,
Robert Sidlow,
Matthew D. Hellmann
(2018).
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
New England Journal of Medicine
, 378
(2)
, 158-168.
https://doi.org/10.1056/nejmra1703481
Identifiers
- DOI
- 10.1056/nejmra1703481